Dorothea Kofahl-Krause

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · The Lancet · 2013 · 1.5K citations

Medicine, Oncology, Pharmacology +6

Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma

Mathias Rummel, S. Al-Batran, Soo-Z. Kim et al. · Journal of Clinical Oncology · 2005 · 440 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Positron Emission Tomography–Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial

Ulrich Dührsen, Stefan Müller, Bernd Hertenstein et al. · Journal of Clinical Oncology · 2018 · 251 citations · Full text

Medicine, Oncology, Chemotherapy +14

Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).

Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · Blood · 2009 · 157 citations

Medicine, Oncology, Pharmacotherapy +6

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line Treatment of Patients with Indolent and Mantle Cell Lymphomas - First Interim Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).

Mathias Rummel, Ulrich von Gruenhagen, N. Niederle et al. · Blood · 2007 · 65 citations

Medicine, Oncology, Pharmacotherapy +12